Kernel

Cybin Inc. (NYSE:CYBN) and Kernel, two companies that undertook a joint feasibility study to evaluate the effects ketamine has on blood flow in the brain in late March, announced their results. In a video shared by Kernel, the company’s CEO and founder, Bryan...

The first study visit to measure the psychedelic effects of ketamine in the cerebral cortex blood flow is underway,  announced Cybin Inc. (NYSE: CYBN), which is sponsoring the research that will make heavy use of Kernel Flow, a quantitative neuroimaging technology. Without...